TriangleBiospecimen Collection (NCT05890352)
Biospecimen Collection trial for Grade 3b Follicular Lymphoma (NCT05890352). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with relapsed or refractory large B-cell lymphoma after one to five regimens, who cannot receive or decline autologous stem-cell transplant.
The idea: add either tazemetostat or zanubrutinib to tafasitamab and lenalidomide, compared with tafasitamab and lenalidomide alone. Tazemetostat blocks an enzyme that controls gene activity; zanubrutinib blocks B-cell growth signals. The study includes dose-finding and compares time before progression. Prior use of these drugs or BTK inhibitors is excluded.
This phase 2 study plans 227 patients. SWOG sponsors it; 99 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.